Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT03259490
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Empagliflozin and Sympathetic Nerve Traffic
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT03254849
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 25358
- Registration Number
- NCT03249506
- Locations
- 🇺🇸
Health ResearchTx, LLC, Trevose, Pennsylvania, United States
Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- CHEOL WHAN LEE, M.D., Ph.D
- Target Recruit Count
- 100
- Registration Number
- NCT03208465
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 12
- Registration Number
- NCT03200782
- Locations
- 🇨🇭
University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism, Basel, Switzerland
Empaglifozin in Early Diabetic Kidney Disease
- Conditions
- Interventions
- Locations
- 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States
Empagliflozin in Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT03157414
- Locations
- 🇳🇴
Oslo University Hospital Rikshospitalet, Oslo, Norway
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT03152552
- Locations
- 🇬🇧
Novartis Investigative Site, Birmingham, United Kingdom
SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Caroline M Kistorp
- Target Recruit Count
- 92
- Registration Number
- NCT03151343
- Locations
- 🇩🇰
Herlev og Gentofte Hospital, Herlev, Denmark
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 40
- Registration Number
- NCT03132181
- Locations
- 🇩🇪
Department of Internal Medicine I RWTH Aachen University Hospital, Aachen, NRW, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.